Immunocytochemical analysis of the cervical Pap smear

Terry Morgan, Michelle Berlin

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Although immunostained cervical Pap smears are not yet FDA approved for clinical use, it is very likely that they will become widely employed in the near future to identify neoplastic squamous and iendocervical glandular cells when screening liquid-based cytological preparations (i.e., SurePath or ThinPrep). The current problem with cytology complemented by high-risk human papillomavirus (HPV) testing is poor specificity. HPV testing provides superior sensitivity, but many women are infected with the virus, while very few have had persistent infections leading to carcinoma. Pathologists routinely use antibodies directed against the cyclin-dependent kinase inhibitor p16 (p16 INK4a) or a combination of antibodies directed against topoisomerase-2-alpha and minichromosome maintenance protein-2 (as in ProEx C) to improve diagnostic precision and accuracy in cervical tissue biopsies. This chapter will describe the immunocytochemical methods used by our group to immunostain cervical Pap smears and provide significantly improved positive predictive value when screening for cervical cancer.

Original languageEnglish (US)
Title of host publicationCervical Cancer: Methods and Protocols
PublisherSpringer New York
Number of pages10
ISBN (Print)9781493920136, 9781493920129
StatePublished - Oct 27 2014


  • CIN1
  • CIN2+
  • HSIL
  • Immunocytochemistry
  • Ki-67
  • Liquid-based cytology
  • LSIL
  • MCM-2
  • p16
  • Pap smear
  • Proexc
  • Topo-2a

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Immunocytochemical analysis of the cervical Pap smear'. Together they form a unique fingerprint.

Cite this